Yesterday, the Federal Circuit found that Biosig’s patent for a heart rate monitor associated with exercise equipment was not invalid.
The defendant Nautilus had argued that the patent was invalid due to indefiniteness. The case reached the Supreme Court, which rejected the Federal Circuit’s “insolubly ambiguous” test. Justice Ginsburg’s written decision instead provided another test for indefiniteness, stating that “a patent is invalid for indefiniteness if its claims, read in light of the specification delineating the patent, and the prosecution history, fail to inform, with reasonable certainty, those skilled in the art about the scope of the invention”.
On remand, the Federal Circuit held that Biosig’s patent was not indefinite even under the new test. Nautilus argued that the term used in the patent referring to “a spaced relationship” between electrodes in the invention is legally indefinite because “the original intrinsic evidence point[s] in two opposite directions, leaving the claims’ boundaries—and thus the potential avenues for follow-on innovation—fundamentally uncertain”.
The Federal Court disagreed. It noted that the Supreme Court’s Nautilus ruling did not hold that terms of degree such as “a spaced relationship” were by definition legally indefinite, just that the patent must provide some standard to measure that degree.
Specifically, it referred back to its previous decision in this case, noting that “an ordinarily skilled artisan would be able to determine this language requires the spaced relationship to be neither infinitesimally small nor greater than the width of a user’s hands”. Furthermore, it said that, looking at the prosecution history, a person skilled in the arts would understand that the spaced relationship “as pertaining to the function of substantially removing EMG signals”, an important part of the invention.
Not so new?
The Federal Circuit also found that despite the Supreme Court directing the lower courts to apply the reasonable certainty standard for indefiniteness, the test is in fact not new. Biosig actually made a similar argument in its briefs and that courts have long held terms such as the ones used in the patent in question to be sufficiently definite. In fact, some observers such as Jason Rantanen of the University of Iowa predicted last month on Patently-O that the test laid out by the Supreme Court in Nautilus would not have much practical effect.
Similarly, Biosig’s counsel argued after the Supreme Court decision that despite the order directing the Federal Circuit to reconsider its patent for indefiniteness, the Supreme Court actually adopted the test that Biosig had argued for.
Judges Newman, Schall, and Wallach sat on the case. Mark David Harris of Proskauer Rose argued for Biosig while John Vandenberg of Klarquist Sparkman represented Nautilus.
The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.
© 2020 Euromoney Institutional Investor PLC. For help please see our FAQs.